Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colorectal cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
389Introduction Colorectalcancer is one of the most common cancers world- wide, particularly in the economically developed world . Large-bowel obstruction caused by advanced coloniccancer occurs in 8%–13% of coloniccancer patients [2–4]. The man- agementof thissevereclinicalconditionhasbeencontroversial .Over thelastdecade,manyarticleshavebeenpublishedon the subject of colonic stenting for malignantcolonic obstruc- tion, including randomized controlled trials (RCTs) and sys- tematic reviews. Thereby (...) ThisGuidelineisanofficialstatementoftheEuropeanSo- cietyof Gastrointestinal Endoscopy(ESGE). Itis a revision of the previously published 2014 Guideline addressing the role of self-expandable metal stents for obstructing colonic and extracolonic cancer. ABBREVIATIONS ASA American Society for Anesthesiologists CI confidence interval CT computed tomography CTC computed tomography colonoscopy ECM extracolonic malignancy ESGE European Societyof Gastrointestinal Endoscopy GRADE Grading of Recommendations Assessment, De- velopment and Evaluation HR
or tests using other markers (e.g. M2-PK) lack formal comparisons of their performance, and integration with other assays needs to be monitored. Screening for high-risk populations is covered in the ESMO guidelines for hereditary gastrointestinalcancer . DIAGNOSIS Symptoms and signs Coloncancer arises from the mucosa of the bowel, growing both into the lumen and the bowel wall, and/or spreading to adjacent organs. Symptoms are associated with relatively largetumours and/or advanced disease (...) and ColonCancer Outcome. JAMA Oncol. 2018; 4(3):309-315. 22. Duffy MJ, van Dalen A, Haglund C et al. Clinical utility of biochemical markers in colorectalcancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer. 2003; 39: 718–727. 23. Locker GY, Hamilton S, Harris J et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinalcancer. J Clin Oncol. 2006; 24: 5313–5327. 24. van der Geest LG, Lam-Boer J, Koopman M et al. Nationwide trends in incidence
of Sciences/Zhejiang Cancer Hospital. 4 Department of Cancer Prevention, Hunan Cancer Hospital, Changsha, China. 5 Office of Cancer Prevention and Treatment, Xuzhou Cancer Hospital, Xuzhou, China. 6 Department of Cancer Prevention, Anhui Provincial Cancer Hospital, Hefei, China. 7 Department of Colorectal Surgery, Tumor Hospital of Yunnan Province/Third Affiliated Hospital of Kunming Medical University, Kunming, China. 8 Department of Medical Oncology, Institute of Cancer and Basic Medicine (ICBM (...) , China. 13 Department of NCD Prevention and Heath Education, Hefei Center for Disease Control and Prevention, Hefei, China. 14 Department of Cancer Prevention, Tumor Hospital of Yunnan Province/Third Affiliated Hospital of Kunming Medical University, Kunming, China. 15 Henan Office for Cancer Control and Research, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China. 16 Department of Epidemiology and Biostatistics, and the Ministry of Education Key Lab
Is 45 really the new 50 in colorectalcancer screening? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca June 29, 2020 (...) Is 45 really the new 50 in colorectalcancer screening? Clinical Question: Should we lower the age that average risk patients commence colorectalcancer screening from 50 to 45? Bottom Line: In developed countries, the incidence of colorectalcancer in persons under 50 years old has increased by 20-30% in the last 20 years. However, the absolute risk increase is only 1-4 per 100,000 persons. Screening average risk patients under age 50 should not be encouraged at this time. Evidence: • Population
Ripretinib (Qinlock) - To treat advanced gastrointestinal-stromal tumors Drug Approval Package: QINLOCK U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: QINLOCK Company: Deciphera Pharmaceuticals, LLC Application Number: 213973 Approval Date: 05/15/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF
Cancer prevention with aspirin in hereditary colorectalcancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lynch syndrome is associated with an increased risk of colorectalcancer and with a broader spectrum of cancers, especially endometrial cancer. In 2011, our group reported long-term cancer outcomes (mean follow-up 55·7 months [SD 31·4]) for participants with Lynch syndrome enrolled (...) outcomes were monitored for at least 10 years from recruitment with English, Finnish, and Welsh participants being monitored for up to 20 years. The primary endpoint was development of colorectalcancer. Analysis was by intention to treat and per protocol. The trial is registered with the ISRCTN registry, number ISRCTN59521990.Between January, 1999, and March, 2005, 937 eligible patients with Lynch syndrome, mean age 45 years, commenced treatment, of whom 861 agreed to be randomly assigned
of Digestive, Endocrine, Oncologic and Liver Transplant Surgery, University Hospital, François Rabelais University, Tours, France. 10 Department of Hepatobiliary, Oncologic and Transplant Surgery, AP-HP, Paul Brousse Hospital, Paris-Sud University, Villejuif, France. PMID: 32209911 DOI: Item in Clipboard Full-text links Cite Abstract Objective: To answer whether synchronous colorectalcancer liver metastases (SLM) should be resected simultaneously with primary cancer or should be delayed. Summary (...) background data: Numerous studies have compared both strategies. All were retrospective and conclusions were contradictory. Methods: Adults with colorectalcancer and resectable SLM were randomly assigned to either simultaneous or delayed resection of the metastases. The primary outcome was the rate of major complications within 60 days following surgery. Secondary outcomes included overall and disease-free survival. Results: A total of 105 patients were recruited. Eighty-five patients (39 and 46
Long-Term ColorectalCancer Incidence and Mortality After a Single Negative Screening Colonoscopy. Current guidelines recommend a 10-year interval between screening colonoscopies, but evidence is limited.To assess the long-term risk for colorectalcancer (CRC) and death from CRC after a high- and low-quality single negative screening colonoscopy.Observational study.Polish Colonoscopy Screening Program.Average-risk individuals aged 50 to 66 years who had a single negative colonoscopy (...) (no neoplastic findings).Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) of CRC after high- and low-quality single negative screening colonoscopy. High-quality colonoscopy included a complete examination, with adequate bowel preparation, performed by endoscopists with an adenoma detection rate of 20% or greater.Among 165 887 individuals followed for up to 17.4 years, CRC incidence (0.28 [95% CI, 0.25 to 0.30]) and mortality (0.19 [CI, 0.16 to 0.21]) were 72% and 81% lower
adenomas 5 mm in size. Future studies may clarify whether length- ening the interval beyond 10 years may be possible. A 10- year follow-up after normal colonoscopy is recommended regardless of indication for the colonoscopy, except for in- dividuals at increased risk for CRC, such as those with his- tory of a hereditary CRC syndrome, personal history of in?ammatory boweldisease, personal history of hereditary cancer syndrome, serrated polyposis syndrome, malignant polyp, personal history of CRC (...) is in keeping with their values and preferences. This article does not include recommendations for follow-up for individuals with hereditary CRC syndromes (eg, Lynch syndrome and familial adenomatous polyposis), in?ammatory boweldisease, a personal history of CRC (includingmalignantpolyps),familyhistoryofCRCorcolo- rectal neoplasia, or serrated polyposis syndrome. As such, our recommendations for follow-up after colonoscopy and polypectomy do not apply to these groups except in cases where polyp ?ndings
?brosis,local residual early carcinoma after endoscopic resection, and non-polypoid colorectal dysplasia in patients with in?ammatory boweldisease. 109 The technique of ESD involves an endoscopic knife for cuttingandsubmucosalinjectantforlifting.Aftersubmuco- sal injection, a circumferential incision is performed to isolate the lesion with 3 or 4 mm surrounding normal mu- cosa. The submucosa under the lesion is injected further. With controlled movements under direct view facilitated with the use (...) months to assess for local recurrence and to clear the colon of synchronous lesions. There is a very high prevalence of synchronous disease in patients with lesions 20 mm. In a large EMR referral cohort with lesions 20 mm, patients had an average of 4 additional conventional adenomas; 40% had an additional advanced adenoma; 20% had an additional lesion 20 mm; and 0.8% had a synchronous cancer not detected by the refer- ring physician. Of those referred for removal of a serrated lesion, 30% had
Regional Therapies for ColorectalCancer Liver Metastases Guideline 2-30a A Quality Initiative of the Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario) Regional Therapies for ColorectalCancer Liver Metastases P. Karanicolas, R. Beecroft, R. Cosby, E. David, M. Kalyvas, E. Kennedy, G. Sapisochin, R. Wong, K. Zbuk and the GastrointestinalDisease Site Group Report Date: March 10, 2020 For information about this document, please contact Dr. Paul Karanicolas or Dr. Robert (...) randomization to disease progression. Guideline 2-30a Section 3: Guideline Methods Overview - March 10, 2020 Page 9 Regional Therapies for ColorectalCancer Liver Metastases Section 3: Guideline Methods Overview This section summarizes the methods used to create the guideline. For the systematic review, see Section 4. THE PROGRAM IN EVIDENCE-BASED CARE The PEBC is an initiative of the Ontario provincial cancer system, Ontario Health (Cancer Care Ontario) (OH [CCO]). The PEBC mandate is to improve the lives
emergency colon or rectal cancer surgery. If resection is not possible, then patients should receive palliative care. , Palliative colostomy should be considered in situations of malignantbowel obstruction. In the assessment of general symptoms, clinicians should determine a patient’s performance status and comorbid conditions, as they can influence the ability to receive and predict the benefit from medical treatment. Diagnosis Recommendations on the methods of diagnosis for patients with colorectal (...) biomarker evaluation guideline. - TABLE 3 Recommendations on Symptom Management TABLE 4 Recommendations on Diagnosis TABLE 5 Recommendations on Staging Symptom Management Recommendations for assisting patients with symptoms of advanced colorectalcancer such as pain or bleeding are in . Discussion. More than 1.8 million patients in the world were diagnosed with colorectalcancer (CRC) in 2018. Among all patients with CRC, 20%-30% have metastatic disease from the outset (synchronous primary tumor
because of palliative treatment and new biological treatments for advanced disease. BetterunderstandingofthenaturalhistoryofGIcancershas shown that most of them are preceded by slowly progressing precancerous conditions or lesions, as well as by early invasive stages, therefore providing opportunities for effective inter- ventions. Beyond the classic adenoma–carcinoma sequence for colorectal carcinogenesis, similar pathways based on metaplasia–dysplasia–cancer progression have been shown for upper GI (...) leadtounderuseorpoorresourcingofhealthfacilities involved inprovidingscreeningservices, with consequent failuretofully realizethe potential benefits to patients. Methods In 2017, the European Society of Gastrointestinal Endoscopy (ESGE) Governing Board established a task force (Public Affairs Working Group led by A.S.) to produce a Position Statement concerning the value of endoscopy for screening purposes in GIcancers. The most prevalent digestivecancers (esophageal squamous cellcarcinoma,esophagealadenocarcinoma,gastric carcinoma